Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Moricizine Hydrochloride

FDA-approved product (tablet, oral), marketed as Ethmozine.

Registered studies
3
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Moricizine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiac arrhythmia

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antiarrhythmics, class i and iii
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Moricizine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moricizine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

    NCT00000556 · start 1995-03

    Registered record
    Registry ID
    NCT00000556
    Conditions
    Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases
    Interventions
    amiodarone; sotalol; propafenone; flecainide; quinidine; moricizine; disopyramide; procainamide; adrenergic beta antagonists; verapamil; diltiazem; digoxin; catheter ablation; pacemaker, artificial
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-03
    Completion
    2002-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases
    Interventionamiodarone; sotalol; propafenone; flecainide +10 more
    PhasePhase 3
    Registry statusCompleted

  • Cardiac Arrhythmia Suppression Trial (CAST)

    NCT00000526 · start 1986-08

    Registered record
    Registry ID
    NCT00000526
    Conditions
    Cardiovascular Diseases; Coronary Disease; Death, Sudden, Cardiac; Heart Arrest; Heart Diseases; Myocardial Infarction; Myocardial Ischemia; Ventricular Arrhythmia
    Interventions
    encainide; flecainide; moricizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1986-08
    Completion
    1998-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Coronary Disease; Death, Sudden, Cardiac; Heart Arrest +4 more
    Interventionencainide; flecainide; moricizine
    PhasePhase 3
    Registry statusCompleted

  • Cardiac Arrhythmia Pilot Study (CAPS)

    NCT00000504 · start 1982-09

    Registered record
    Registry ID
    NCT00000504
    Conditions
    Arrhythmia; Cardiovascular Diseases; Heart Diseases; Ventricular Arrhythmia
    Interventions
    encainide; moricizine; flecainide; imipramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1982-09
    Completion
    1985-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArrhythmia; Cardiovascular Diseases; Heart Diseases; Ventricular Arrhythmia
    Interventionencainide; moricizine; flecainide; imipramine
    PhasePhase 2
    Registry statusCompleted